Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2018 | Venetoclax and ruxolitinib treatment strategies for myeloma

A number of novel treatment strategies for multiple myeloma (MM) are being studied. A few such studies are discussed here by Noopur Raje, MD, of Massachusetts General Hospital Cancer Center, Boston, MA. Prof. Raje covers the use of venetoclax in combination with carfilzomib for relapsed/refractory MM (NCT02899052). She also mentions the combination of low-dose lenalidomide with the JAK inhibitor ruxolitinib (NCT03110822). This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting in Chicago, IL.